Home
Search

Letters, Testimony & Comments

BIO submits letters, testimony, and comments to government and regulatory bodies throughout the United States and around the world.

Featured Letters, Testimony, & Comments
Notice of Request for Public Comments on Section…
The Biotechnology Innovation Organization (BIO) offers this submission in response to the request by the Department of Commerce for comments on section 232 national security investigation of imports of pharmaceuticals and pharmaceutical ingredients…
Learn more
BIO Letter to Congressional Leadership on the…
One thing that we can all agree on is the need to give our children a fighting chance so they can lead long and productive lives. That is why it is critical to pass the bipartisan Give Kids a Chance Act and ensure the Pediatric Priority Review…
Learn more
John F. Crowley's One-Year Anniversary Letter to…
Dear Colleagues, This month marks my one-year anniversary as BIO's CEO. Like most of us in biotech, this post has been a labor of love. At no time in my 25-year career in this industry have I ever witnessed such awe-inspiring science. Today, we…
Learn more
All Letters, Testimony & Comments
  • Show All
Search
Results
BIO Submits Comments Re: Medicare Program; Part B Drug Payment Model [CMS-1670-P]
May 9, 2016
The Biotechnology Innovation Organization appreciates this opportunity to submit comments on the Centers for Medicare and Medicaid Services’ proposed rule entitled Medicare Program; Part B Drug Payment Model...
Follow-Up on BIO’s Comments in Response to the ICER Value Framework
May 4, 2016
The Biotechnology Innovation Organization (BIO) would like to take the opportunity to follow-up and expand on the feedback we originally submitted to the Institute for Clinical and Economic Review (ICER) in October 2015 on the ICER Value Framework …
Cures Acceleration Network: Legislative Text
March 10, 2016
The Cures Acceleration Network, passed in the recently enacted healthcare reform bill, will provide funding to public and private entities to bridge the gap between basic research and cures for patients.
BIO’s comments to the USDA on the biomass crop assistance program enacted by the 2008 Farm Bill
March 10, 2016
Comments are regarding conservation and stewardship requirements, matching payments, establishment costs and annual payments, disclosure of competitively sensitive information, invasiveness determination and review, consistency with existing FSA…
Small Business Early Stage Investment Program: Legislative Text
March 10, 2016
The Small Business Early Stage Investment Program would provide matching funds for investment companies who invest in small, high tech companies, including biotech firm.
BIO letter in support of H.R. 5418
March 10, 2016
To establish a pilot program for educating district court judges on patent related issues.
Presentation: "Global Health Challenges: How Industry is Addressing Global Health", presented at the University of Virginia in June 2008
March 10, 2016
Global Health Challenges: How Industry is Addressing Global Health
Ted Roumel, Vice President for Research Innovation & Commercialization at the University of Maryland Biotechnology Institute, USA
March 10, 2016
Innovation And The Global Research Enterprise WORLD HEALTH ORGANIZATION GENEVA—NOVEMBER 2007 THEODORE J. ROUMEL VICE PRESIDENT for RESEARCH, INNOVATION AND COMMERCIALIZATION UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE
BIO Testimony to the House Judiciary Committee Concerning the Hearing on Patent Reform
March 10, 2016
Diran Makinde, Network Director, NEPAD Biosciences, West Africa Biosciences Network (WABNet), Senegal
March 10, 2016
Government's role in developing solutions for diseases that disproportionately affect developing countries